CN115054811A - Medicine balloon catheter device capable of forming endogenous vascular stent - Google Patents
Medicine balloon catheter device capable of forming endogenous vascular stent Download PDFInfo
- Publication number
- CN115054811A CN115054811A CN202210990198.7A CN202210990198A CN115054811A CN 115054811 A CN115054811 A CN 115054811A CN 202210990198 A CN202210990198 A CN 202210990198A CN 115054811 A CN115054811 A CN 115054811A
- Authority
- CN
- China
- Prior art keywords
- drug
- balloon catheter
- balloon
- catheter device
- cavity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 84
- 229940079593 drug Drugs 0.000 title claims abstract description 68
- 230000002792 vascular Effects 0.000 title claims abstract description 12
- 239000002105 nanoparticle Substances 0.000 claims abstract description 44
- 229920001690 polydopamine Polymers 0.000 claims abstract description 16
- 210000005077 saccule Anatomy 0.000 claims abstract description 15
- 102000003566 TRPV1 Human genes 0.000 claims abstract description 13
- 101150016206 Trpv1 gene Proteins 0.000 claims abstract description 13
- 239000003146 anticoagulant agent Substances 0.000 claims abstract description 10
- 229940127219 anticoagulant drug Drugs 0.000 claims abstract description 9
- 239000002245 particle Substances 0.000 claims description 8
- 239000011248 coating agent Substances 0.000 claims description 7
- 238000000576 coating method Methods 0.000 claims description 7
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 6
- 229960002897 heparin Drugs 0.000 claims description 6
- 229920000669 heparin Polymers 0.000 claims description 6
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 5
- 229910052802 copper Inorganic materials 0.000 claims description 5
- 239000010949 copper Substances 0.000 claims description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 4
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 claims description 4
- 239000011593 sulfur Substances 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- 125000003277 amino group Chemical group 0.000 claims description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 3
- 229960000956 coumarin Drugs 0.000 claims description 2
- 235000001671 coumarin Nutrition 0.000 claims description 2
- 230000008878 coupling Effects 0.000 claims description 2
- 238000010168 coupling process Methods 0.000 claims description 2
- 238000005859 coupling reaction Methods 0.000 claims description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 claims 2
- OMZSGWSJDCOLKM-UHFFFAOYSA-N copper(II) sulfide Chemical compound [S-2].[Cu+2] OMZSGWSJDCOLKM-UHFFFAOYSA-N 0.000 abstract description 44
- 210000004204 blood vessel Anatomy 0.000 abstract description 16
- 102000008186 Collagen Human genes 0.000 abstract description 15
- 108010035532 Collagen Proteins 0.000 abstract description 15
- 229920001436 collagen Polymers 0.000 abstract description 15
- 230000000638 stimulation Effects 0.000 abstract description 11
- 150000002500 ions Chemical class 0.000 abstract description 10
- 230000003902 lesion Effects 0.000 abstract description 7
- 238000000034 method Methods 0.000 abstract description 6
- 230000008569 process Effects 0.000 abstract description 6
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 abstract description 5
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 5
- 229910001431 copper ion Inorganic materials 0.000 abstract description 5
- 210000000497 foam cell Anatomy 0.000 abstract description 5
- 230000008021 deposition Effects 0.000 abstract description 4
- 241000894006 Bacteria Species 0.000 abstract description 3
- 230000015572 biosynthetic process Effects 0.000 abstract description 3
- 210000000170 cell membrane Anatomy 0.000 abstract description 3
- 208000015181 infectious disease Diseases 0.000 abstract description 3
- 230000008929 regeneration Effects 0.000 abstract description 3
- 238000011069 regeneration method Methods 0.000 abstract description 3
- 210000004509 vascular smooth muscle cell Anatomy 0.000 abstract description 3
- 238000002560 therapeutic procedure Methods 0.000 abstract description 2
- 230000002776 aggregation Effects 0.000 abstract 1
- 238000004220 aggregation Methods 0.000 abstract 1
- BWFPGXWASODCHM-UHFFFAOYSA-N copper monosulfide Chemical class [Cu]=S BWFPGXWASODCHM-UHFFFAOYSA-N 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 description 6
- 238000002626 targeted therapy Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 239000012890 simulated body fluid Substances 0.000 description 5
- 230000005540 biological transmission Effects 0.000 description 4
- LBJNMUFDOHXDFG-UHFFFAOYSA-N copper;hydrate Chemical compound O.[Cu].[Cu] LBJNMUFDOHXDFG-UHFFFAOYSA-N 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 108091006146 Channels Proteins 0.000 description 3
- 230000033115 angiogenesis Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000003143 atherosclerotic effect Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000013146 percutaneous coronary intervention Methods 0.000 description 3
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000002872 contrast media Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 150000003948 formamides Chemical class 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000002159 nanocrystal Substances 0.000 description 2
- 239000002086 nanomaterial Substances 0.000 description 2
- 238000012638 near-infrared photothermal therapy Methods 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- 238000002428 photodynamic therapy Methods 0.000 description 2
- 238000007626 photothermal therapy Methods 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- 231100000216 vascular lesion Toxicity 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 229910021594 Copper(II) fluoride Inorganic materials 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 1
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 108010062740 TRPV Cation Channels Proteins 0.000 description 1
- 102100029613 Transient receptor potential cation channel subfamily V member 1 Human genes 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- UYJXRRSPUVSSMN-UHFFFAOYSA-P ammonium sulfide Chemical compound [NH4+].[NH4+].[S-2] UYJXRRSPUVSSMN-UHFFFAOYSA-P 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-O azanium;hydron;hydroxide Chemical compound [NH4+].O VHUUQVKOLVNVRT-UHFFFAOYSA-O 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000007211 cardiovascular event Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000007213 cerebrovascular event Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229910000365 copper sulfate Inorganic materials 0.000 description 1
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 1
- XTVVROIMIGLXTD-UHFFFAOYSA-N copper(II) nitrate Chemical compound [Cu+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O XTVVROIMIGLXTD-UHFFFAOYSA-N 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 1
- GWFAVIIMQDUCRA-UHFFFAOYSA-L copper(ii) fluoride Chemical compound [F-].[F-].[Cu+2] GWFAVIIMQDUCRA-UHFFFAOYSA-L 0.000 description 1
- LLVVIWYEOKVOFV-UHFFFAOYSA-L copper;diiodate Chemical compound [Cu+2].[O-]I(=O)=O.[O-]I(=O)=O LLVVIWYEOKVOFV-UHFFFAOYSA-L 0.000 description 1
- 238000002586 coronary angiography Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- WNAHIZMDSQCWRP-UHFFFAOYSA-N dodecane-1-thiol Chemical compound CCCCCCCCCCCCS WNAHIZMDSQCWRP-UHFFFAOYSA-N 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 210000001595 mastoid Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- -1 nitrogen-containing organic compound Chemical class 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000012221 photothermal agent Substances 0.000 description 1
- DPLVEEXVKBWGHE-UHFFFAOYSA-N potassium sulfide Chemical compound [S-2].[K+].[K+] DPLVEEXVKBWGHE-UHFFFAOYSA-N 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 230000027756 respiratory electron transport chain Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 229910052979 sodium sulfide Inorganic materials 0.000 description 1
- GRVFOGOEDUUMBP-UHFFFAOYSA-N sodium sulfide (anhydrous) Chemical compound [Na+].[Na+].[S-2] GRVFOGOEDUUMBP-UHFFFAOYSA-N 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- YUKQRDCYNOVPGJ-UHFFFAOYSA-N thioacetamide Chemical compound CC(N)=S YUKQRDCYNOVPGJ-UHFFFAOYSA-N 0.000 description 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M25/1002—Balloon catheters characterised by balloon shape
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0021—Catheters; Hollow probes characterised by the form of the tubing
- A61M25/0023—Catheters; Hollow probes characterised by the form of the tubing by the form of the lumen, e.g. cross-section, variable diameter
- A61M25/0026—Multi-lumen catheters with stationary elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0043—Catheters; Hollow probes characterised by structural features
- A61M25/0045—Catheters; Hollow probes characterised by structural features multi-layered, e.g. coated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M25/104—Balloon catheters used for angioplasty
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0601—Apparatus for use inside the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M2025/1043—Balloon catheters with special features or adapted for special applications
- A61M2025/105—Balloon catheters with special features or adapted for special applications having a balloon suitable for drug delivery, e.g. by using holes for delivery, drug coating or membranes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M2025/1043—Balloon catheters with special features or adapted for special applications
- A61M2025/1086—Balloon catheters with special features or adapted for special applications having a special balloon surface topography, e.g. pores, protuberances, spikes or grooves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0601—Apparatus for use inside the body
- A61N2005/0602—Apparatus for use inside the body for treatment of blood vessels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
- A61N2005/0659—Radiation therapy using light characterised by the wavelength of light used infrared
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Media Introduction/Drainage Providing Device (AREA)
Abstract
The invention belongs to the field of medical appliances, and provides a drug balloon catheter device capable of forming an endogenous blood vessel stent; comprises a saccule catheter, polydopamine modified copper sulfide nano-particles, an anticoagulant drug and a near-infrared light source; in the process of balloon interventional therapy, through near-infrared light stimulation inside the balloon, the resonance of copper sulfide nanoparticle ions is promoted, a TRPV1 channel on a plasma membrane of a vascular smooth muscle cell is activated, the formation of foam cells is inhibited, the adhesion and aggregation of platelets are inhibited, the deposition of target lesion collagen is promoted, and the endogenous autologous vascular stent is formed by solidifying on a vascular wall; the copper ions are released, so that the regeneration of blood vessels can be promoted, the antibacterial effect can be exerted, and the probability of bacteria infection in the operation is effectively reduced.
Description
Technical Field
The invention relates to the field of medical instruments, in particular to a drug balloon catheter device capable of forming an endogenous blood vessel stent.
Background
Atherosclerosis (AS) is a chronic inflammatory and metabolic disease that is the leading cause of cardiovascular and cerebrovascular events, an early atherosclerotic event being the accumulation of cholesterol and triglycerides in Vascular Smooth Muscle Cells (VSMCs) and monocytes/macrophages leading to the formation of foam cells; in recent years, the treatment of AS is continuously advanced in a breakthrough way, and the wide application of antiplatelets, statins and interventional therapy (PCI) greatly promotes the prognosis treatment of AS patients; however, plaque stabilization remains the most problematic clinical problem at present, and there is a need to develop more effective means and drugs for treating atherosclerotic diseases.
Photothermal therapy is used as an important treatment means for cancer treatment, and means that a nano material is used as a photothermal agent, light energy is converted into heat energy under the irradiation of external laser, cell membranes are loosened by utilizing high temperature, the permeability of the cell membranes is changed, and the uptake of tumor cells to the nano material is increased by utilizing the advantages of photothermal conversion efficiency and biocompatibility; wherein the copper sulfide nanoparticles which are often used as catalysts can realize photothermal conversion and photodynamic therapy; photothermal therapy has been reported to be applied to atherosclerotic diseases, and the result shows that copper sulfide nanoparticles activate TRPV1 signal channel through photothermal, so that the generation of foam cells is reduced, and atherosclerosis is relieved.
Meanwhile, the copper sulfide nano-particles release copper ions, can induce the expression of growth factors, provide a microenvironment beneficial to the growth of vascular endothelial cells, and can promote collagen deposition and angiogenesis; copper ions also have a bactericidal effect, and are firmly adsorbed with a microbial film with negative electricity, so that protein is solidified, the activity of cell synthetase is damaged, and cells lose division and proliferation capacity and die, for example, 317L stainless steel containing copper has good antibacterial performance on staphylococcus aureus and escherichia coli, and inflammatory reaction is effectively inhibited; scientists find that under the irradiation of near infrared light, cuprous ions released by copper sulfide nanocrystals in a physiological environment can be enhanced, and the copper sulfide nanocrystals interact with a surrounding biological environment to generate an oxidation-reduction reaction and generate electron transfer, so that the photodynamic therapy characteristic is embodied.
Polydopamine (PDA) is an endogenous nitrogen-containing organic compound, and due to the fact that a large number of hydroxyl groups exist on the surface of the compound, the hydrophilic property and the biocompatibility of the medicine can be improved.
The implantation of a Drug Eluting Stent (DES) in Percutaneous Coronary Intervention (PCI) is one of the main means for treating coronary heart disease at present; however, after the drug eluting stent is implanted, about 5 percent of in-stent restenosis rate still exists, and due to the limitation of self structure and size, the application of the stent in the part of bifurcation lesion and small-diameter coronary vessel (less than 2.5 mm) lesion is limited; at present, the antiproliferative drug is directly exposed in blood by the drug eluting balloon, so that the drug coating can not be dissolved and washed and lost in the blood before reaching a diseased region, the bioavailability is low, and the drug release targeting property is poor.
Published patent application No.: 101211404, providing a drug delivery cannula, which mainly comprises an elastic inner layer, an elastic outer layer, and at least one drug, wherein the drugs are enclosed between the elastic inner layer and the elastic outer layer; in the using process, when the therapeutic agent is nano-particles, the guide wire of the balloon catheter is further replaced by light, and the near infrared light can irradiate the nano-particles through the light to heat and increase the temperature, so that cancer cells are killed.
However, the prior art still has the following disadvantages: (1) the operation is complex in the use process of the near infrared light, and time and labor are wasted; (2) the near infrared light has low utilization efficiency, high energy loss and long illumination time; (3) the application range is narrow.
According to the background, copper sulfide nanoparticles (CuS NPs) with different particle sizes are prepared by a sulfur source and a copper source, amino groups of a TRPV1 antibody and carboxyl groups on the surfaces of (CuSNPs) are coupled to form amides, a CuS-TRPV1 is obtained, a polydopamine layer (PDA) is modified on the surface of the CuS-TRPV1, non-covalent bonds of the PDA are utilized for self-polymerization to load drugs on the surface of the polydopamine layer, the drug-loaded copper sulfide nanoparticles capable of realizing near-infrared photothermal therapy are prepared, in the process of balloon intervention, anticoagulant drugs on the surface inhibit platelet aggregation, and then near-infrared light stimulation in the balloon is utilized to promote copper sulfide nanoparticle ion resonance to be released to a target vascular lesion, so that the generation of foam cells is reduced, meanwhile, collagen deposition of the target vascular lesion is promoted, and the vessel wall is solidified to form an autologous vascular stent; meanwhile, copper ions are slowly released in the degradation process of the copper sulfide nanoparticles, so that the regeneration of blood vessels can be promoted, the antibacterial effect can be exerted, and the probability of bacteria infection in operation is effectively reduced.
Disclosure of Invention
The invention aims to overcome the defects of the traditional medicine balloon catheter and a medicine eluting stent, and provides a medicine balloon catheter device capable of forming an endogenous intravascular stent, which is simple to operate, time-saving and labor-saving, high in near infrared light utilization rate, low in energy loss and short in illumination time.
In order to achieve the purpose, the invention adopts the technical scheme that: preparing copper sulfide nanoparticles (CuS NPs) with different particle sizes from a soluble sulfur source and a copper source, coupling amino groups of a TRPV1 antibody and carboxyl groups on the surfaces of (CuSNPs) to form amides to obtain CuS-TRPV1, modifying a polydopamine layer (PDA) on the surface of CuS-TRPV1, loading a medicament on the surface of the polydopamine layer by utilizing non-covalent bond auto-polymerization of the PDA to prepare a medicament-loaded copper sulfide nanoparticle capable of realizing near-infrared photothermal therapy, and dispersing the medicament-loaded copper sulfide nanoparticle into a water-soluble dispersant to form a medicament-loaded coating material; and (3) spraying the drug-loaded coating material on the surface of the balloon by using an ultrasonic spraying method, and drying the balloon in vacuum to obtain the drug-eluting balloon catheter containing drugs with different particle sizes.
Preferably, the TRPV1 antibody: molecular weight 100KDa, manufacturer: ABClonal.
Preferably, the soluble sulfur source is one or more of thiourea, sodium sulfide and hydrate thereof, potassium sulfide and hydrate thereof, ammonium sulfide and hydrate thereof, thioacetamide, thioglycolic acid or dodecyl mercaptan; the soluble copper source is one or more of copper nitrate and hydrate thereof, copper chloride and hydrate thereof, copper iodate and hydrate thereof, copper sulfate and hydrate thereof, copper acetate and hydrate thereof or copper fluoride and hydrate thereof.
Preferably, the near infrared light source is attached to the surface of the balloon inner tube.
Preferably, the polydopamine modified CuS TRPV1 nano-particle with the outer layer provided with the anticoagulant drug is coated on the surface of the score or the surface of the microneedle.
Preferably, the anticoagulant drug is heparin drug or coumarin drug, wherein the molecular weight of the heparin is 1700-30000 KD.
Preferably, the near infrared light of 700-1100nm is selected as the light source, the number of the light sources is 1-10, and the light source is spherical or cylindrical.
Preferably, the balloon has a diameter of 1-14mm and a length of 5-350 mm.
Preferably, the balloon catheter is a single-cavity tube or a double-cavity tube or a three-cavity tube or a four-cavity tube, and the balloon inner tube is a single-cavity tube or a three-cavity tube.
Preferably, when the balloon catheter is a single-cavity tube, the balloon inner tube is a single-cavity tube or a three-cavity tube; when the balloon catheter and the balloon inner tube are both single-lumen tubes, the power line is fixed on the balloon inner tube by glue or a wire; when the balloon catheter is a double-cavity tube, the balloon inner tube is a single-cavity tube or a three-cavity tube; when the balloon catheter is a three-cavity tube, the balloon inner tube is a single-cavity tube or a three-cavity tube; when the balloon catheter is a four-cavity tube, the balloon inner tube is a single-cavity tube or a three-cavity tube.
Preferably, the balloon is a scored surface or a microneedle surface.
Preferably, one end of the power line is directly connected with the power switch or connected with the power socket, and the diameter of the power line is 0.1mm-0.5 mm.
Preferably, the balloon catheter device is of the rapid exchange type or of the total exchange type.
When the lesion position is treated by balloon intervention, the resonance of copper sulfide nanoparticle ions is promoted through near-infrared light stimulation in the balloon, the copper sulfide nanoparticle ions are released to the lesion position of a target blood vessel, the generation of foam cells is reduced, and meanwhile, the collagen deposition of the target lesion is promoted, and an endogenous autologous vascular stent is formed; meanwhile, copper ions released by the copper sulfide nano particles can promote the regeneration of blood vessels, play an antibacterial effect and effectively reduce the probability of bacteria infection in the operation.
The invention has the advantages that: (1) the light source can quickly convert light energy into heat energy in the balloon, so that the time is short and the efficiency is high; (2) the application range is wide, and the device realizes the treatment of blood vessels at the superficial part and deep part of the human body; (3) the near infrared light penetrability medium is controllable (the penetration distance is the radius of the saccule, and the penetrability substance can be artificially limited), so that the energy absorbed by the target part is also controllable, and the treatment effect and the safety are ensured; (4) the surface of the microneedle can break through the obstruction of an endothelial cell layer, promote the direct contact of a balloon surface substance (CuS TRPV1) and collagen in a cytoplasmic matrix, and greatly improve the efficiency of generating an endogenous scaffold.
Drawings
Fig. 1 is a structural schematic diagram of a drug balloon catheter device capable of forming an endogenous blood vessel stent.
Fig. 2 is a schematic diagram of the internal structure of the balloon with different external shapes of light sources.
Fig. 3 is a cross-sectional structure diagram of the 4-balloon catheter part when the balloon catheter is a four-lumen tube.
FIG. 4 is a schematic cross-sectional view of the 4-balloon catheter site when the balloon catheter is a single lumen tube and the balloon inner tube is a three lumen tube.
FIG. 5 is a schematic cross-sectional view of the 4-balloon catheter portion when the balloon catheter and the balloon inner tube are single-lumen tubes.
In the figure, 1 balloon, 2 light source, 3 developing ring, 4 balloon catheter, 5 tube seat, 6 balloon inner tube, 7 drug-loaded coating (CuS TRPV1 nano particle with anticoagulant drug on outer layer), 8 power line, 9 switch or power socket, 10 liquid cavity, 11 power line positive electrode cavity channel, 12 power line negative electrode cavity channel, and 13 guide wire cavity.
Detailed Description
The following examples are combined to prepare a drug balloon catheter device capable of forming an endogenous blood vessel stent, and the treatment effect and the angiogenesis capacity of the drug balloon catheter device on atherosclerotic plaques are discussed.
Example 1: synthesizing and characterizing the drug-loaded copper sulfide nano-particles.
The synthesis steps of the copper sulfide nano-particles are as follows: mixing 1-20mLCuCl 2 ·2H 2 O(1.077mg mL −1 ) Aqueous solution and 1-20mL sodium citrate (1.0mg mL) −1 ) Adding the aqueous solution into 3-60mL of water, and stirring the mixture at room temperature for 30 min; then 5-100 mu LNa 2 S·9H 2 O(743.92mg mL −1 ) Adding the aqueous solution into the mixture, stirring for 5min, and transferring into an oil bath at 90 ℃; the reaction is maintained at this temperature for 10-30min to form CuS NPs.
3.36 to 33Mu. mol EDC (1-ethyl- (3-dimethylaminopropyl) carbodiimide) and 3.36-33.6. mu. mol NHS (N-hydroxysuccinimide) were added to 1-10mL of CuS NPs (0.4mg mL) −1 ) Reacting in the solution at room temperature for 30 min; then 2. mu.g of TRPV1 (capsaicin receptor) antibody was added to the solution, and stirred for 12 hours to prepare CuS-TRPV1 nanoparticles.
Weighing 20mg of synthesized CuS-TRPV1, ultrasonically dispersing in 10mL of Tris-HCl buffer solution, adding 10mg of dopamine, magnetically stirring and reacting for 4.5h in an oil bath at 50 ℃, and centrifugally separating to obtain the polydopamine-modified nanoparticle copper sulfide.
Suspending the copper sulfide nanoparticles in a phosphate buffer solution, adding 10mg of heparin, stirring for 24 hours, performing centrifugal separation at a rotating speed of 10000r/min, and washing for 3 times by using the phosphate buffer solution to obtain the heparin-coated copper sulfide particles.
Under a transmission electron microscope, the copper sulfide nano particles are uniform in size, good in dispersity, in a specification spherical shape, and 5-30nm in particle size; under a transmission electron microscope, the drug-loaded copper sulfide nanoparticles have uniform size, good dispersibility, specification spherical shape and particle size of 50-100 nm.
Example 2: 1 light source medicine balloon catheter device.
A drug balloon catheter device capable of forming an endogenous intravascular stent comprises a balloon 1, a light source 2, a developing ring 3, a balloon catheter 4, a tube seat 5, a balloon inner tube 6, a drug-loaded coating 7, a power line 8 and a switch or power socket 9.
One end of the balloon 1 is connected with a balloon catheter 4, and the balloon catheter 4 is preferably a four-cavity catheter; the other end is connected with an inner tube 6, and the developing ring 3 is fixed on the inner tube 6.
One end of the catheter 4 is connected with a tube seat 5, the tube seat 5 comprises a guide wire cavity opening and a liquid cavity opening, and the balloon can enter a lesion position along a guide wire and can be filled with the balloon.
The surface of the balloon 1 is provided with a drug-loaded coating 7.
The inner tube 6 is provided with the light source 2, the light source 2 is connected with the switch or the power socket 9 through the power cord 8, and the power cord 8 can be fixed on the balloon catheter 4.
Preferred are balloons with a diameter of 1-2mm and a length of 5-10 mm.
Example 3: 3 light source medicine balloon catheter devices.
The number of light sources was changed to 3 as in example 2.
Preferred are balloons with a diameter of 3-5mm and a length of 20-60 mm.
Example 4: 5 light source medicine balloon catheter devices.
The number of light sources was changed to 5 in the same manner as in example 2.
Preferred are balloons with a diameter of 6-8mm and a length of 80-150 mm.
Example 5: 7 light source medicine balloon catheter devices.
The number of light sources was changed to 7 as in example 2.
A balloon with a diameter of 9-11mm and a length of 170-250mm is preferred.
Example 6: 9 light source medicine balloon catheter devices.
The number of light sources was changed to 9 as in example 2.
Balloons with a diameter of 11-13mm and a length of 250-300mm are preferred.
Example 7: the influence of the drug-loaded copper sulfide nano-spherical capsule on the angiogenesis capacity of the drug-loaded copper sulfide nano-particles is examined.
Establishing an atherosclerosis model by using New Zealand white rabbits (2.5-3.0 kg), and randomly dividing into a targeted treatment group and a control group; selecting an abdominal aorta area with the diameter of 3.0mm for quantitative coronary angiography measurement, adopting a balloon catheter device with the length of 30mm, inflating under 6atm, and simultaneously performing in-vitro near infrared light intervention for 60 s; and taking a target blood vessel after 9 months of operation, and measuring the content of collagen in the plaque by Masson staining of the blood vessel by adopting a double-antibody sandwich enzyme-linked immunosorbent assay.
The content of collagen in the plaque is observed by testing Masson staining, and the result shows that: (a) the collagen content of the naked sacculus group is 26 percent; (b) in vitro near infrared light stimulation and medicine carrying copper sulfide nano-particles, wherein the content of balloon collagen is 66%; (c) the balloon collagen content is 49 percent without near infrared light stimulation and drug-loaded copper sulfide nano-particles; (d) a saccule is used as a device on the surface of a microneedle, near-infrared light in the saccule stimulates the medicine-carrying copper sulfide nano-particles, and the content of saccule collagen is 89%; (e) a saccule is used as a device for scoring the surface, near-infrared light in the saccule stimulates the medicine-carrying copper sulfide nano particles, and the content of the saccule collagen is 80%; (f) the saccule is used as a device on the surface of the mastoid, near-infrared light in the saccule stimulates the nano copper sulfide particles carrying medicine, and the content of the saccule collagen is 73 percent.
Example 8: according to the concentration of each ion in human plasma, SBF simulated body fluid is configured to establish a human blood vessel model; the balloon is divided into a targeted therapy group and a control group at random, the targeted therapy group and the control group are inflated under 6atm for 60s continuously to release the drugs, the device of the embodiment 2 is adopted, the balloon is the surface of a microneedle, the near infrared light in the balloon stimulates (containing 1 light source), the drug-loaded copper sulfide nanoparticles, and the drug release amount of the balloon reaches 88%.
Example 9: according to the concentration of each ion in human plasma, SBF simulated body fluid is configured to establish a human blood vessel model; the balloon is divided into a targeted therapy group and a control group at random, the inflation is carried out under 6atm, the drug release is carried out for 60s continuously, the device of the embodiment 3 is adopted, the balloon is the surface of a microneedle, and the drug release amount of the balloon is up to 85% under the stimulation of near infrared light (containing 3 light sources) in the balloon and the drug-loaded copper sulfide nanoparticle balloon.
Example 10: according to the concentration of each ion in human plasma, SBF simulated body fluid is configured to establish a human blood vessel model; the balloon is divided into a targeted therapy group and a control group at random, the inflation is carried out under 6atm, the drug release is carried out for 60s continuously, the device of the embodiment 4 is adopted, the balloon is the surface of a microneedle, and the drug release amount of the balloon is 80% under the stimulation of near infrared light (containing 5 light sources) in the balloon and the drug-loaded copper sulfide nanoparticle balloon.
Example 11: according to the concentration of each ion in human plasma, SBF simulated body fluid is configured to establish a human blood vessel model; the balloon is divided into a targeted therapy group and a control group at random, the inflation is carried out under 6atm, the drug release is carried out for 60s continuously, the device of the embodiment 5 is adopted, the balloon is the surface of a microneedle, and the drug release amount of the balloon is up to 83% under the stimulation of near infrared light (containing 7 light sources) in the balloon and the drug-loaded copper sulfide nanoparticle balloon.
Example 12: according to the concentration of each ion in human plasma, SBF simulated body fluid is configured to establish a human blood vessel model; the balloon is divided into a targeted therapy group and a control group at random, the inflation is carried out under 6atm, the drug release is carried out for 60s continuously, the device of the embodiment 9 is adopted, the balloon is the surface of a microneedle, and the drug release amount of the balloon is up to 82% under the stimulation of near infrared light (containing 9 light sources) in the balloon and the drug-loaded copper sulfide nanoparticle balloon.
Comparative example 1: the test process is the same as that of example 8, and the drug release amount of the copper sulfide nanoparticle balloon without near infrared light stimulation and drug loading reaches 28%.
Comparative example 2: the test process is the same as that of example 8, and the in vitro near-infrared light stimulation and drug-loaded copper sulfide nano-particle balloon drug release amount reaches 52 percent.
The results of the examples show that, under the same test conditions, the drug release effect of the drug balloon catheter device stimulated by infrared light inside the balloon is far greater than that of a device which is not stimulated by near infrared light or a device which is stimulated by near infrared light outside the balloon; the study in example 7 found that the collagen content: (d) > (e) > (f) > (b) > (c) > (a); generally, the near-infrared light-emitting device has good curative effect on the aspects of drug release rate and collagen content, and compared with the near-infrared light-emitting device in the patent, the near-infrared light-emitting device has low transmission efficiency, large energy loss, long irradiation time, complex operation and long operation time; the invention has the advantages of convenient operation, short operation time, reduced pain of patients, high near infrared light transmission efficiency, small energy loss and short irradiation time, and the near infrared light only passes through the physiological saline or the contrast agent or the mixed solution of the physiological saline and the contrast agent and a layer of the saccule wall.
The above embodiments are only preferred embodiments of the present invention, and are not intended to limit the scope of the invention, and all modifications and additions made thereto according to the content of the claims of the present invention are also included in the claims of the present invention.
Claims (7)
1. A drug balloon catheter device capable of forming an endogenous intravascular stent comprises a balloon catheter, a balloon inner tube, polydopamine modified CuS TRPV1 nanoparticles with an anticoagulant drug on the outer layer, a near-infrared light source, a power line and a tube seat; the balloon is a scored surface or a microneedle surface; the near-infrared light source is attached to the surface of the balloon inner tube; coating polydopamine modified CuS TRPV1 nanoparticles with an anticoagulant drug on the outer layer on the surface of a score or the surface of a microneedle; selecting near infrared light of 700-1100nm as a light source, wherein the number of the light sources is 1-10, and the light sources are spherical or cylindrical; the diameter of the saccule is 1-14mm, and the length is 5-350 mm; wherein the polydopamine modified CuS TRPV1 nano particle with the outer layer provided with the anticoagulant drug is as follows: preparing CuS nano-particles with different particle sizes by using a soluble sulfur source and a copper source, coupling amino groups of a TRPV1 antibody and carboxyl groups on the surfaces of the CuS nano-particles to form amide to obtain CuS-TRPV1, modifying a polydopamine layer on the surfaces of the CuS-TRPV1, and finally wrapping an anticoagulant drug on the surface of the polydopamine.
2. The drug balloon catheter device of claim 1, wherein the drug balloon catheter device is capable of forming an endogenous vascular stent, and comprises: the anticoagulant drug is heparin drug or coumarin drug, wherein the molecular weight of the heparin is 1700-30000 KD.
3. The drug balloon catheter device of claim 1, wherein the drug balloon catheter device is capable of forming an endogenous vascular stent, and comprises: the diameter of the nano particle is 5-300 nm.
4. The drug balloon catheter device of claim 1, wherein the drug balloon catheter device is capable of forming an endogenous vascular stent, and comprises: the balloon catheter is a single-cavity tube or a double-cavity tube or a three-cavity tube or a four-cavity tube, and the balloon inner tube is a single-cavity tube or a three-cavity tube.
5. The drug balloon catheter device of claim 1, wherein the drug balloon catheter device is capable of forming an endogenous vascular stent, and comprises: when the balloon catheter is a single-lumen tube, the diameter of the balloon is 1-5 mm; when the cavity is double-cavity, the diameter of the saccule is 3-10 mm; when the catheter is a three-cavity catheter or a four-cavity catheter, the diameter of the saccule is 4-14 mm.
6. The drug balloon catheter device of claim 1, wherein the drug balloon catheter device is capable of forming an endogenous vascular stent, and comprises: one end of the power line is directly connected with the power switch or the power socket, and the diameter of the power line is 0.1mm-0.5 mm.
7. The drug balloon catheter device of claim 1, wherein the drug balloon catheter device is capable of forming an endogenous vascular stent, and comprises: the balloon catheter device is of the rapid exchange type or of the total exchange type.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210990198.7A CN115054811A (en) | 2022-08-18 | 2022-08-18 | Medicine balloon catheter device capable of forming endogenous vascular stent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210990198.7A CN115054811A (en) | 2022-08-18 | 2022-08-18 | Medicine balloon catheter device capable of forming endogenous vascular stent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115054811A true CN115054811A (en) | 2022-09-16 |
Family
ID=83207944
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210990198.7A Pending CN115054811A (en) | 2022-08-18 | 2022-08-18 | Medicine balloon catheter device capable of forming endogenous vascular stent |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115054811A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115998669A (en) * | 2023-01-10 | 2023-04-25 | 中国海洋大学 | Copper sulfide nano enzyme-antibacterial peptide-hyaluronic acid composite microneedle and preparation method and application thereof |
| CN117503984A (en) * | 2024-01-05 | 2024-02-06 | 浙江百迪生物科技有限公司 | Platelet-rich plasma-copper sulfide composite nanofiber dressing and preparation method thereof |
| WO2024103445A1 (en) * | 2022-11-18 | 2024-05-23 | 深圳先进技术研究院 | Neuromodulation system |
Citations (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050228260A1 (en) * | 2003-03-14 | 2005-10-13 | Phillip Burwell | Light generating device to intravascular use |
| US20080057590A1 (en) * | 2006-06-07 | 2008-03-06 | Mickey Urdea | Markers associated with arteriovascular events and methods of use thereof |
| CN102416217A (en) * | 2011-09-06 | 2012-04-18 | 微创医疗器械(上海)有限公司 | Sacculus expansion catheter for drug treatment |
| CN102512747A (en) * | 2011-12-27 | 2012-06-27 | 微创医疗器械(上海)有限公司 | Medicine eluting balloon catheter |
| US20120316436A1 (en) * | 2011-06-10 | 2012-12-13 | Cook Medical Technologies Llc | Balloon catheter with three lumens |
| US20160136397A1 (en) * | 2014-11-17 | 2016-05-19 | Quattro Vascular Pte Ltd. | Balloon catheter system and method of using same |
| US20160158513A1 (en) * | 2014-12-03 | 2016-06-09 | Industry-Academic Cooperation Foundation Yonsei University | Balloon catheter having micro needles and manufacturing method for the same |
| US20180056086A1 (en) * | 2015-03-18 | 2018-03-01 | Mor Research Applications Ltd. | Percutaneous modification of vascular extracellular matrix to prevent and treat vascular restenosis |
| CN107847645A (en) * | 2015-05-13 | 2018-03-27 | 波士顿科学国际有限公司 | The medicine equipment of drug coat |
| US20180228537A1 (en) * | 2017-02-13 | 2018-08-16 | Shanghai Golden Leaf Medtech Co., Ltd. | Medical device comprising a balloon-stent assembly and methods of using the same |
| CN110201289A (en) * | 2019-05-15 | 2019-09-06 | 武汉福脉医疗科技有限公司 | A kind of medicament elution sacculus and preparation method thereof |
| CN111991420A (en) * | 2020-02-20 | 2020-11-27 | 成都因诺生物医药科技有限公司 | Pharmaceutical use of composition for treating atherosclerosis |
| CN112618922A (en) * | 2020-12-30 | 2021-04-09 | 上海心至医疗科技有限公司 | Preparation method of drug balloon, prepared drug balloon and application thereof |
| CN113144296A (en) * | 2020-12-31 | 2021-07-23 | 山东瑞安泰医疗技术有限公司 | Drug eluting balloon for enabling blood vessel to generate endogenous stent and preparation method thereof |
| CN113975405A (en) * | 2021-07-27 | 2022-01-28 | 中山大学 | Nanoparticle targeting TRPV1, and preparation method and application thereof |
| CN114010917A (en) * | 2021-11-05 | 2022-02-08 | 广东博迈医疗科技股份有限公司 | Double-medicine administration balloon |
| CN114225185A (en) * | 2021-11-05 | 2022-03-25 | 广东博迈医疗科技股份有限公司 | Drug delivery balloon and drug delivery device |
| WO2022105065A1 (en) * | 2020-11-20 | 2022-05-27 | 东莞天天向上医疗科技有限公司 | Bumpy expanding balloon and production and use method therefor |
-
2022
- 2022-08-18 CN CN202210990198.7A patent/CN115054811A/en active Pending
Patent Citations (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050228260A1 (en) * | 2003-03-14 | 2005-10-13 | Phillip Burwell | Light generating device to intravascular use |
| US20080057590A1 (en) * | 2006-06-07 | 2008-03-06 | Mickey Urdea | Markers associated with arteriovascular events and methods of use thereof |
| US20120316436A1 (en) * | 2011-06-10 | 2012-12-13 | Cook Medical Technologies Llc | Balloon catheter with three lumens |
| CN102416217A (en) * | 2011-09-06 | 2012-04-18 | 微创医疗器械(上海)有限公司 | Sacculus expansion catheter for drug treatment |
| CN102512747A (en) * | 2011-12-27 | 2012-06-27 | 微创医疗器械(上海)有限公司 | Medicine eluting balloon catheter |
| US20160136397A1 (en) * | 2014-11-17 | 2016-05-19 | Quattro Vascular Pte Ltd. | Balloon catheter system and method of using same |
| US20160158513A1 (en) * | 2014-12-03 | 2016-06-09 | Industry-Academic Cooperation Foundation Yonsei University | Balloon catheter having micro needles and manufacturing method for the same |
| US20180056086A1 (en) * | 2015-03-18 | 2018-03-01 | Mor Research Applications Ltd. | Percutaneous modification of vascular extracellular matrix to prevent and treat vascular restenosis |
| CN107847645A (en) * | 2015-05-13 | 2018-03-27 | 波士顿科学国际有限公司 | The medicine equipment of drug coat |
| US20180228537A1 (en) * | 2017-02-13 | 2018-08-16 | Shanghai Golden Leaf Medtech Co., Ltd. | Medical device comprising a balloon-stent assembly and methods of using the same |
| CN110201289A (en) * | 2019-05-15 | 2019-09-06 | 武汉福脉医疗科技有限公司 | A kind of medicament elution sacculus and preparation method thereof |
| CN111991420A (en) * | 2020-02-20 | 2020-11-27 | 成都因诺生物医药科技有限公司 | Pharmaceutical use of composition for treating atherosclerosis |
| WO2022105065A1 (en) * | 2020-11-20 | 2022-05-27 | 东莞天天向上医疗科技有限公司 | Bumpy expanding balloon and production and use method therefor |
| CN112618922A (en) * | 2020-12-30 | 2021-04-09 | 上海心至医疗科技有限公司 | Preparation method of drug balloon, prepared drug balloon and application thereof |
| CN113144296A (en) * | 2020-12-31 | 2021-07-23 | 山东瑞安泰医疗技术有限公司 | Drug eluting balloon for enabling blood vessel to generate endogenous stent and preparation method thereof |
| CN113975405A (en) * | 2021-07-27 | 2022-01-28 | 中山大学 | Nanoparticle targeting TRPV1, and preparation method and application thereof |
| CN114010917A (en) * | 2021-11-05 | 2022-02-08 | 广东博迈医疗科技股份有限公司 | Double-medicine administration balloon |
| CN114225185A (en) * | 2021-11-05 | 2022-03-25 | 广东博迈医疗科技股份有限公司 | Drug delivery balloon and drug delivery device |
Non-Patent Citations (1)
| Title |
|---|
| WEN GAO ET AL: "Copper sulfide nanoparticles as a photothermal switch for TRPV1 signaling to attenuate atherosclerosis", 《NATURE COMMUNICATIONS》 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024103445A1 (en) * | 2022-11-18 | 2024-05-23 | 深圳先进技术研究院 | Neuromodulation system |
| CN115998669A (en) * | 2023-01-10 | 2023-04-25 | 中国海洋大学 | Copper sulfide nano enzyme-antibacterial peptide-hyaluronic acid composite microneedle and preparation method and application thereof |
| CN115998669B (en) * | 2023-01-10 | 2024-05-24 | 中国海洋大学 | Copper sulfide nano enzyme-antibacterial peptide-hyaluronic acid composite microneedle and preparation method and application thereof |
| CN117503984A (en) * | 2024-01-05 | 2024-02-06 | 浙江百迪生物科技有限公司 | Platelet-rich plasma-copper sulfide composite nanofiber dressing and preparation method thereof |
| CN117503984B (en) * | 2024-01-05 | 2024-04-19 | 浙江百迪生物科技有限公司 | Platelet-rich plasma-copper sulfide composite nanofiber dressing and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN115054811A (en) | Medicine balloon catheter device capable of forming endogenous vascular stent | |
| CN113144296B (en) | Drug eluting balloon for enabling blood vessels to self-grow endogenous stent and preparation method thereof | |
| ES2300604T3 (en) | MEDICINAL DEVICE FOR THE SUPPLY OF MEDICINAL PRODUCT. | |
| CN108653754B (en) | Hyaluronic acid targeted polydopamine coated phase-change type liquid fluorocarbon nano ultrasonic contrast agent | |
| CN107583049B (en) | Preparation method of injectable hydrogel with photo-thermal property | |
| CN107596366B (en) | A kind of diagnoses and treatment preparation and its preparation method and application with multiple stimulation response type drug controlled-releasing function | |
| CN105288620B (en) | A kind of preparation method of Jenner's popped rice for neoplasm targeted therapy | |
| CN111760024B (en) | Permeation enhanced gold nanocluster drug-loaded targeting preparation and preparation method and application thereof | |
| ES2727712T3 (en) | Modified surface capable of having bactericidal, bacteriostatic and antimicrobial activity, procedure for obtaining and using it | |
| CN109248327B (en) | Mesoporous silica drug delivery system and application thereof | |
| CN107982534A (en) | Preparation method of chitosan/copper sulphide nano composite hollow ball and products thereof and application | |
| Ding et al. | Photothermal nanohybrid hydrogels for biomedical applications | |
| CN109820838A (en) | A kind of photo-thermal controlled-release hydrogen nano material and the preparation method and application thereof | |
| CN111388450A (en) | CO gas-chemodynamic therapy-assisted anti-tumor nano delivery carrier, preparation method and application in anti-tumor drugs | |
| Du et al. | Injectable nanocomposite hydrogels for cancer therapy | |
| Liu et al. | Biomedical Micro‐/Nanomotors: Design, Imaging, and Disease Treatment | |
| WO2006084913A2 (en) | Device for treatment of rectal disorders, and manufacturing process for the same, involving nitric oxide | |
| CN106692971B (en) | Gold nano-grade heat radiotherapy medicine carrier and preparation method and application thereof | |
| Weng et al. | Research progress of stimuli-responsive ZnO-based nanomaterials in biomedical applications | |
| Hoseinzadeh et al. | Effective treatment of intractable diseases using nanoparticles to interfere with vascular supply and angiogenic process | |
| CN105194693B (en) | For CT imagings and the golden shell parcel iodo nano-particle of photo-thermal therapy and its preparation | |
| Witharana et al. | Drug delivery systems: A new frontier in nano-technology | |
| CN112546025B (en) | Preparation method of Ce6@CMCS-DSP-IPI549 anti-tumor nano-delivery system | |
| CN110585116B (en) | Double-response chitin-based nanogel for cancer treatment and preparation method thereof | |
| CN104984354A (en) | Polyacrylic acid-calcium phosphate composite nano-drug carrier and preparing method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information |
Inventor after: Zhang Haijun Inventor after: Zhou Guangtai Inventor after: Zhou Chao Inventor before: Zhang Haijun Inventor before: Zhou Guangtai Inventor before: Chu Tongchao Inventor before: Zhou Chao |
|
| CB03 | Change of inventor or designer information | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20220916 |
|
| WD01 | Invention patent application deemed withdrawn after publication |